Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heartflow, Inc. filings document a Nasdaq-listed Delaware medical technology company focused on AI software for coronary artery disease. Its recent 8-K reports furnish operating results, investor presentations and Regulation FD disclosures, while also recording capital-structure events tied to its completed initial public offering and repayment and termination of a credit agreement.
The company’s proxy materials cover annual meeting matters, director elections, auditor ratification and stockholder voting mechanics. As an emerging growth company, Heartflow’s filings also identify governance, exchange listing, financial reporting and public-company status disclosure areas relevant to a commercial-stage medical technology issuer.
Wellington Management Group LLP and related entities report beneficial ownership of 5,894,070 shares of Heartflow, Inc. common stock, representing 6.9% of the class as of 12/31/2025. The shares are held of record by clients of various Wellington investment advisers.
Wellington has shared voting power over 5,877,783 shares and shared dispositive power over 5,894,070 shares, with no sole voting or dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Heartflow.
Heartflow, Inc. director Julie A. Cullivan reported a planned stock sale. On February 5, 2026, she sold 8,000 shares of Common Stock of Heartflow at $27.32 per share, in an open-market transaction.
The filing states this trade was carried out under a pre-arranged Rule 10b5-1 trading plan that she adopted on September 12, 2025. After the sale, she continued to hold 36,413 shares of Heartflow common stock in direct ownership.
BCLS Fund III Investments, LP, a Bain Capital Life Sciences affiliated fund and 10% owner of Heartflow, Inc., reported a sale of 2,000,000 shares of Heartflow common stock on February 4, 2026 at $28.05 per share. After this transaction, BCLS Fund III Investments indirectly held 10,448,158 shares of Heartflow common stock. Related Bain Capital Life Sciences entities may be deemed to share voting and dispositive power over these securities and each disclaims beneficial ownership except to the extent of its pecuniary interest.
A shareholder has filed a Rule 144 notice to sell up to 8,000 shares of common stock through Fidelity Brokerage Services on the NASDAQ, with an approximate sale date of February 5, 2026. The issuer reports 85,158,719 shares outstanding.
The shares to be sold were acquired via stock option exercises paid in cash, including 6,849 shares on June 15, 2024 and 1,151 shares on December 15, 2024. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
Heartflow, Inc. furnished an investor presentation in connection with an upcoming investor conference. The company posted the presentation on its website and attached it as Exhibit 99.1 to this report. The materials are provided under Regulation FD, and the company states that the information is being furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.
Heartflow, Inc. director Mr. Lightcap reported buying 40,000 shares of Heartflow common stock on 12/16/2025 in an open market purchase at a weighted average price of $26.342 per share. After this transaction, he holds 40,000 shares directly. The filing also lists additional indirect beneficial ownership through affiliated investment entities, including 4,615,542 shares held by HCPCIV 1, LLC, 833,075 shares held by HealthCor Partners Fund II, L.P., and 1,248,939 shares held by HealthCor Partners Fund, L.P., for which he is a controlling member and disclaims beneficial ownership beyond his economic interest.
HeartFlow, Inc. (HTFL) disclosed a routine insider transaction by its Chief Executive Officer and Director on 11/07/2025. The filing reports 1,339 shares of common stock reflected as a code F transaction at $32.56 per share, representing shares retained by the issuer to satisfy income tax withholding upon the vesting and net settlement of previously reported RSUs.
Following this administrative withholding event, the reporting person beneficially owns 431,909 shares, held directly.
HeartFlow, Inc. (HTFL) reported an insider transaction by its Chief Financial Officer on a Form 4. On 11/07/2025, the officer had 471 shares of common stock withheld/disposed at $32.56 under transaction code F, which reflects shares retained by the company to satisfy tax withholding upon the vesting and net settlement of previously reported RSUs. Following this event, the officer beneficially owns 144,912 shares directly.
Heartflow, Inc. filed a Form 4 reporting a tax-related share withholding from an RSU vesting. On 11/07/2025, 81 shares of common stock were withheld by the issuer at $32.56 per share under transaction code F.
The reporting person is an officer (Chief Accounting Officer, VP) and now directly holds 10,115 shares following the transaction. Code F reflects shares retained to satisfy income tax withholding obligations on previously reported RSUs, rather than an open-market sale.
Heartflow, Inc. reported Q3 2025 results. Revenue was $46,276 thousand with gross profit of $35,415 thousand. Operating loss was $15,099 thousand, and net loss was $50,855 thousand, driven in part by a $32,117 thousand increase in the fair value of the common stock warrant liability and a $6,360 thousand loss on extinguishment of debt.
The company completed its IPO on August 11, 2025, selling 19,166,667 shares at $19.00 per share for gross proceeds of approximately $364.2 million (net cash inflow of $332,784 thousand). All redeemable convertible preferred stock converted into 51,226,348 common shares, and 6,470,743 shares were issued upon conversion of 2025 convertible notes. A 1‑for‑2.92 reverse stock split was effected on July 31, 2025.
As of September 30, 2025, cash and cash equivalents were $291,167 thousand; the prior term loan was fully repaid (balance $0 versus $136,431 thousand at year‑end 2024). Shares outstanding were 85,158,719 as of October 31, 2025.